Retinal organoid and gene editing for basic and translational research

Vision Res. 2023 Sep:210:108273. doi: 10.1016/j.visres.2023.108273. Epub 2023 Jun 10.

Abstract

The rapid evolution of two technologies has greatly transformed the basic, translational, and clinical research in the mammalian retina. One is the retinal organoid (RO) technology. Various induction methods have been created or adapted to generate species-specific, disease-specific, and experimental-targeted retinal organoids (ROs). The process of generating ROs can highly mimic the in vivo retinal development, and consequently, the ROs resemble the retina in many aspects including the molecular and cellular profiles. The other technology is the gene editing, represented by the classical CRISPR-Cas9 editing and its derivatives such as prime editing, homology independent targeted integration (HITI), base editing and others. The combination of ROs and gene editing has opened up countless possibilities in the study of retinal development, pathogenesis, and therapeutics. We review recent advances in the ROs, gene editing methodologies, delivery vectors, and related topics that are particularly relevant to retinal studies.

Keywords: Delivery; Differentiation; Gene editing; Pluripotent stem cells; Retinal diseases; Retinal organoid.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Gene Editing* / methods
  • Humans
  • Mammals
  • Organoids
  • Reactive Oxygen Species
  • Retina
  • Translational Research, Biomedical*

Substances

  • Reactive Oxygen Species